Intranasal Arc-engineered exosomes reduce Alzheimer pathology by restoring autophagy
The targeted nanoplatform cleared amyloid deposits and suppressed neuroinflammation in an Alzheimer's model by inhibiting mTOR signaling.
In an animal model of Alzheimer's disease, intranasal delivery of neural stem cell-derived exosomes engineered with the scaffolding protein Arc reduced key disease signs. Researchers first analyzed 143,214 single nuclei, identifying excitatory neurons as the main site of cellular damage marked by disrupted proteostasis and autophagy pathways. To counter these deficits, the team engineered exosomes to overexpress Arc, leveraging its natural neuronal affinity and neurorestorative actions. Following intranasal administration, the Arc-engineered exosomes accumulated efficiently in the central nervous system. The treatment significantly lowered beta-amyloid deposition, dampened neuroinflammation, and repaired injured neurons. Mechanistic analysis showed that these engineered exosomes restored cellular homeostasis by suppressing mTOR signaling and reactivating autophagy.
Why it matters
Loss of proteostasis and impaired autophagy are central drivers of brain aging and neurodegeneration. Using targeted nanoplatforms to re-engage these cellular cleanup pathways provides a targeted strategy to protect vulnerable neurons.
Caveats
The findings are restricted to an animal model and cannot be directly translated to human patients without clinical testing. In addition, the abstract does not report sample sizes, specific cognitive metrics, or long-term safety data.
- Arc-engineered exosomes
- Chronic inflammation
- Disabled macroautophagy
- Loss of proteostasis
- Autophagy
- mTOR signalling
- ARC
- Alzheimer's disease
- Amyloid-beta
The paper
Targeting neuronal injury with intranasal Arc-engineered exosomes rescues cognitive deficits in Alzheimer's disease via the mTOR-autophagy pathway
Sun C, Sha S, Kang J et al.
Nanomedicine · 25 Sep 2026